Foundation Medicine, Inc. FMI and COTA, Inc. today announced an
agreement to capture and analyze comprehensive genomic, clinical outcome, and
cost data from patients who have undergone testing with FoundationOne^®. The
resulting dataset is designed to provide health care providers and payers with
the supporting clinical outcomes and costs evidence that inform value-based
reimbursement decisions and cancer treatment.
“Eliminating inefficiencies and improving patient care requires actionable
insights supported by complete, integrated data,” said Eric Schultz, CEO of
COTA. “This unprecedented collaboration with Foundation Medicine incorporates
the most comprehensive genomic profiling data with COTA's unique real-world,
longitudinal clinical outcomes and cost of care data to provide insights that
enable both physicians and payers to move toward value-based treatment and
reimbursement practices.”
The collaboration will first capture clinical outcomes for patients with Stage
IV non-small cell lung cancer (NSCLC), the leading cancer killer of men and
women in this country, who have undergone testing with FoundationOne. The
resulting longitudinal data will aim to further demonstrate the clinical
utility of comprehensive genomic profiling for patients with Stage IV NSCLC
and to inform potential value-based reimbursement decisions from payers. The
combination of genomic data, clinical information, outcomes data and economic
data will provide critical insights for both payers and physicians to fully
endorse the clinical and economic benefits associated with the application of
comprehensive genomic profiling in this disease setting.
“The capture of clinical outcomes resulting from treatment selection informed
by our comprehensive genomic profiles is essential to demonstrating the
clinical and economic value of FoundationOne and to expanding utilization and
access for these tests,” said Michael Pellini, CEO of Foundation Medicine. “We
are pleased to work in partnership with COTA on this initiative to provide
additional clarity of the impact on patient outcomes and cost of care that
result from our comprehensive genomic profiling tests. We look forward to
enhancing our robust collection of evidence with this integrated data package
to support broader payer coverage and value-based reimbursement for our
tests.”
Initially, Foundation Medicine and COTA will identify patients who are newly
diagnosed with Stage IV NSCLC and are enrolled in a health plan that has
agreed to participate in this phase of the collaboration. Subsequent phases of
the collaboration, which are currently under discussion, may include
integration across the remainder of the clinical scenarios included in the
appropriate use of FoundationOne and FoundationOne Heme.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in